Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Amicus Drops Epidermolysis Bullosa Candidate Following Phase III Failure

Executive Summary

CEO Crowley points to the need to focus on a pair of Fabry candidates, including the pending NDA for migalastat, and notes that other companies have reached Phase III in EB.

Advertisement

Related Content

FDA Reversal Gives Amicus Renewed Hope For US Oral Fabry Launch
Amicus Eyes Broad Future Label For Migalastat After Huge Filing Setback
Amicus Eyes Breakthrough Drug, PRV Revenue In Scioderm Buy

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

SC099484

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel